Can-Fite BioPharma (CANF) Receivables (2013 - 2021)

Can-Fite BioPharma's (CANF) quarterly Receivables came in at $3.6 million in Q2 2020, down 59.31% on a QoQ basis from $8.8 million in Q4 2019.

Can-Fite BioPharma (CANF) Receivables (2013 - 2021) Analysis & Trends

Can-Fite BioPharma (CANF) has 6 years of Receivables data on file, last reported at $3.6 million in Q2 2020.

Quarterly Receivables changed N/A year-over-year to $3.6 million in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $3.6 million (changed N/A YoY) and the FY2019 annual result came in at $8.8 million, up 9.17% from the prior year.
Receivables eased to $3.6 million in Q2 2020, from $8.8 million in the prior quarter.
In the past five years, Receivables ranged from a high of $8.8 million in Q4 2019 to a low of $3.6 million in Q2 2020.
A 3-year average of $6.8 million and a median of $8.0 million in 2018 frame the typical range for Receivables.
The widest YoY moves for Receivables: up 9.17% in 2019, down 9.17% in 2019.
Tracing CANF's Receivables over 3 years: stood at $8.0 million in 2018, then grew by 9.17% to $8.8 million in 2019, then plunged by 59.31% to $3.6 million in 2020.
The last three Receivables figures came in at $3.6 million (Q2 2020), $8.8 million (Q4 2019), and $8.0 million (Q4 2018), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	138.04 Bn	130.18 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	85.98 Bn	77.98 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	64.37 Bn	59.19 Bn	1.37 Bn	1.93 Bn
4	Moderna	57.67 Bn	52.53 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	41.94 Bn	36.84 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	912.74 Mn
7	BioNTech SE	27.75 Bn	9.35 Bn	668.28 Mn	1.09 Bn
8	Insmed	27.24 Bn	26.08 Bn	358.27 Mn	215.33 Mn
9	Royalty Pharma	27.03 Bn	26.20 Bn	-	-
10	Can-Fite BioPharma	2.78 Mn	-8.77 Mn	-	-

Download Data